trigram

This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

trigram	frequency
the development of	1154
as well as	903
the use of	890
the united states	622
of the vaccine	602
in the united	566
one of the	464
severe acute respiratory	420
acute respiratory syndrome	415
the immune response	405
based on the	382
the presence of	376
in order to	369
the production of	357
due to the	356
and immunogenicity of	355
respiratory syncytial virus	354
a number of	352
cd t cells	347
the immune system	339
of the virus	331
the number of	328
safety and immunogenicity	320
the risk of	307
development of a	297
h n influenza	288
respiratory syndrome coronavirus	288
in addition to	282
immune responses to	277
immune response to	276
been shown to	276
the efficacy of	269
such as the	267
t cell responses	267
the role of	262
of a vaccine	257
a variety of	255
vaccines have been	249
for use in	249
influenza a virus	247
it has been	247
world health organization	238
of the immune	238
cd t cell	238
need to be	237
the induction of	237
can be used	236
years of age	234
immune responses in	233
for the development	231
in terms of	227
of the disease	224
there is a	222
the case of	221
as a result	219
the absence of	218
the ability to	213
found to be	211
there is no	201
cellular immune responses	197
have been developed	196
has been shown	195
safety and efficacy	193
humoral and cellular	193
in the case	193
have been used	191
because of the	190
in the development	189
the need for	185
some of the	185
the importance of	179
the immunogenicity of	179
be used to	179
shown to be	179
in developing countries	178
human immunodeficiency virus	178
of the most	177
the expression of	175
has also been	175
newcastle disease virus	175
high levels of	173
hepatitis b virus	171
of influenza a	171
cd and cd	168
have also been	166
the ability of	166
development of vaccines	164
the fact that	164
morbidity and mortality	164
response to the	162
associated with the	161
for vaccine development	161
that can be	160
immunogenicity of a	159
in the vaccine	158
in clinical trials	157
the s protein	156
in response to	156
in combination with	154
immune response in	154
as a vaccine	153
part of the	153
the impact of	152
the effect of	152
the level of	152
in the elderly	150
the h n	150
middle east respiratory	148
to be a	148
the surface of	148
and cd t	148
east respiratory syndrome	148
in the absence	146
h n virus	146
in healthy adults	146
of dna vaccines	144
of influenza virus	143
a result of	143
and cellular immune	143
the identification of	143
a dna vaccine	142
protective immunity against	142
well as the	141
weeks of age	141
according to the	140
in patients with	140
in the s	140
analysis of the	138
likely to be	138
on the other	137
vaccine has been	137
the generation of	136
the emergence of	136
in the us	136
as compared to	136
the potential for	135
the vaccine is	135
the introduction of	135
of infectious diseases	134
the world health	134
the incidence of	134
compared to the	133
the context of	133
is associated with	132
is one of	132
was found to	132
in the presence	132
an immune response	131
the potential to	131
immune responses against	131
most of the	130
a single dose	130
and safety of	128
of the world	128
the most common	128
the time of	128
the spread of	128
of h n	128
to protect against	127
have shown that	127
the other hand	126
has been used	126
is the most	126
a total of	126
the safety and	126
in this study	125
a and b	125
and efficacy of	125
the prevention of	125
influenza vaccine in	124
to develop a	124
in mice and	124
understanding of the	124
in the context	124
the control of	124
of immune responses	124
the lack of	123
can also be	123
to the vaccine	123
is based on	122
at the time	122
the treatment of	122
safe and effective	122
was used to	121
in the past	121
of the antigen	121
vaccine based on	121
the majority of	120
in animal models	119
vaccine in the	119
the possibility of	119
the end of	118
in the usa	118
a review of	118
vaccinia virus ankara	117
research and development	117
used as a	117
may not be	117
expression of the	117
to the development	116
h n vaccine	116
west nile virus	116
efficacy of a	116
the vaccine was	115
of the viral	115
on the surface	115
months of age	115
depending on the	115
in vaccine development	114
the basis of	113
been used to	113
a range of	113
modified vaccinia virus	113
role in the	113
immunogenicity of the	113
live attenuated vaccines	113
be able to	112
the safety of	112
of the sars	112
as part of	112
of a recombinant	112
be used as	112
the respiratory tract	112
cellular and humoral	112
the site of	111
related to the	111
influenza virus infection	110
immune response against	110
in which the	110
for disease control	110
hepatitis b vaccine	110
to determine the	110
has not been	109
virus infection in	109
efficacy of the	109
structure of the	109
based on a	109
the potential of	109
balb c mice	109
a vaccine against	108
use of the	108
it is important	107
at the same	107
to reduce the	107
of a new	107
have been shown	107
is important to	105
humoral immune response	105
the same time	105
and in the	105
a phase i	105
it is not	104
hepatitis b surface	104
more likely to	104
many of the	104
protective efficacy of	104
be used in	103
as an adjuvant	103
humoral immune responses	103
is likely to	103
used in the	103
that have been	102
rift valley fever	102
to be the	102
correlates of protection	102
of the population	102
led to the	101
of neutralizing antibodies	101
b surface antigen	101
vaccines based on	101
an increase in	100
of a novel	100
used for the	100
in the field	99
the availability of	99
for the prevention	99
adaptive immune responses	99
centers for disease	99
influenza a viruses	98
are able to	98
in the uk	98
protective immune responses	98
in recent years	98
to evaluate the	97
the effectiveness of	97
that the vaccine	97
of hepatitis b	96
the innate immune	96
the activation of	96
a h n	95
in vitro and	95
to improve the	94
and in vivo	94
have been reported	94
of influenza vaccine	94
needs to be	94
t cell response	94
a combination of	94
control and prevention	94
immune response and	94
with respect to	93
caused by the	93
use of a	93
protective immune response	93
the host cell	93
to enhance the	93
the most important	93
and characterization of	93
vaccines in the	93
in a phase	92
the vaccine construct	92
of vaccines against	92
has been reported	92
antibody responses to	92
phase i clinical	92
evaluation of the	92
and can be	92
innate and adaptive	91
the administration of	91
immune responses and	91
development of an	91
have not been	90
h n viruses	90
in contrast to	90
disease control and	89
emerging infectious diseases	89
increase in the	89
nature of the	88
was shown to	88
of the first	88
protective immunity in	88
of severe acute	88
in the first	87
to assess the	87
a series of	87
it should be	86
h n and	86
some of these	86
in the same	86
a systematic review	86
their ability to	86
development of new	85
single dose of	85
in the future	85
to increase the	85
were found to	85
the delivery of	84
the united kingdom	84
it may be	84
cells in the	84
on the basis	84
in some cases	84
associated with a	84
specific cd t	84
and it is	84
the design of	84
the need to	84
of vaccines and	83
vaccine development and	83
mice immunized with	83
and t cell	83
and control of	83
included in the	82
for the treatment	82
and h n	82
of the s	82
end of the	82
upper respiratory tract	81
efficacy and safety	81
review of the	81
is an important	81
to be used	81
to ensure that	81
mhc class i	81
can lead to	80
there are no	80
have to be	80
t cells in	80
be used for	80
with or without	80
an important role	80
mucosal and systemic	80
of vaccine development	80
the influenza virus	80
vitro and in	79
been used for	79
are associated with	79
the amount of	79
for the production	79
vesicular stomatitis virus	79
parts of the	79
the results of	78
activation of the	78
showed that the	78
the cost of	78
prevention and control	78
the application of	77
recent advances in	77
the injection site	77
the vaccine and	77
influenza virus vaccine	77
development of the	77
there has been	77
it is possible	77
specific immune responses	77
studies have shown	76
to induce a	76
of the same	76
which can be	76
the formation of	76
and public health	76
the virus is	76
food and drug	76
vaccination in the	76
of cd t	75
is a major	75
has been demonstrated	75
were used to	75
the development and	75
been associated with	74
derived from the	74
vaccines can be	74
in the host	74
virus in the	74
have been identified	74
of the human	74
immunogenicity and safety	74
should not be	74
vaccine against sars	73
it can be	73
of immune response	73
important role in	73
appears to be	73
mucosal immune responses	73
lower respiratory tract	73
it is a	72
considered to be	72
mediated immune responses	72
herpes simplex virus	72
in the early	72
of plasmid dna	72
the duration of	72
and humoral immune	72
the spike protein	72
the effects of	72
of new vaccines	71
is responsible for	71
present in the	71
a vaccine is	71
a new vaccine	71
antibody responses in	71
in rhesus macaques	71
to be vaccinated	71
the form of	71
referred to as	71
with regard to	71
that could be	71
are likely to	70
the disease is	70
central nervous system	70
of the influenza	70
the nature of	70
has been developed	70
both humoral and	70
responsible for the	70
against infectious diseases	70
has led to	70
in the last	70
cell responses in	70
the onset of	70
the success of	70
t cell epitopes	70
diseases such as	70
and development of	69
all rights reserved	69
the prevalence of	69
advisory committee on	69
mechanism of action	69
the antibody response	69
of the host	69
for a vaccine	69
and drug administration	69
the field of	69
addition to the	69
contribute to the	69
responses in the	69
of these vaccines	69
this is the	69
the frequency of	68
the present study	68
live attenuated influenza	68
the copyright holder	68
are based on	68
antibody response to	68
in humans and	68
committee on immunization	68
immunodeficiency virus type	68
a live attenuated	68
to be more	68
study of the	68
inactivated influenza vaccine	68
may lead to	68
there have been	68
n and h	68
major histocompatibility complex	68
are needed to	68
members of the	67
the severity of	67
of the protein	67
pandemic h n	67
it is also	67
avian influenza virus	67
an effective vaccine	67
lead to the	67
the quality of	67
immunization with a	67
could be used	67
for development of	67
the mechanism of	67
n influenza virus	67
of public health	67
of mice with	67
systemic and mucosal	67
there is an	67
vaccines that are	66
immunogenicity of an	66
involved in the	66
of action of	66
may be a	66
as shown in	66
the type of	66
the addition of	66
vaccine in healthy	66
disease caused by	66
administration of the	66
may also be	66
have been tested	66
an overview of	66
as a potential	65
on immunization practices	65
surface of the	65
a vaccine for	65
of the pandemic	65
of this vaccine	65
a license to	65
the process of	65
immune response is	65
a public health	65
wide range of	64
a role in	64
each of the	64
responses in mice	64
different types of	64
influenzae type b	64
due to their	64
innate immune response	64
risk of infection	64
the pathogenesis of	64
to be safe	64
there was no	64
at the site	64
when compared to	64
are the most	64
clinical trials in	64
evaluation of a	64
two doses of	63
for human use	63
assessment of the	63
to display the	63
cytotoxic t lymphocytes	63
over the past	63
in the form	63
that it is	63
neutralizing antibodies and	63
there are many	63
phase i ii	63
universal influenza vaccine	63
was able to	63
vaccines for the	63
of vaccines in	62
influenza a h	62
the response to	62
is caused by	62
cell responses to	62
which is a	62
in many countries	62
of age and	62
were able to	62
of protective immunity	62
conflict of interest	62
that there is	62
a safe and	62
there are several	62
of live attenuated	62
to be effective	62
mouth disease virus	61
the immune responses	61
granted medrxiv a	61
license to display	61
recommendations of the	61
antigen presenting cells	61
against h n	61
the beginning of	61
of adverse events	61
medrxiv a license	61
demonstrated that the	61
against hepatitis b	61
the preprint in	61
a wide range	61
is the author	61
thought to be	61
display the preprint	61
who has granted	61
h n pandemic	61
more than one	61
of the vaccines	61
spread of the	61
neutralizing antibody responses	61
the author funder	61
has granted medrxiv	61
vaccine delivery systems	60
will need to	60
immunity to the	60
in the control	60
vaccine and the	60
higher levels of	60
innate immune system	60
this type of	60
at the injection	60
the host immune	60
the discovery of	60
and treatment of	60
the concept of	60
and evaluation of	60
in this case	60
that of the	60
around the world	59
yet to be	59
this version posted	59
i clinical trial	59
was associated with	59
administration of a	59
in the production	59
in a study	59
and the vaccine	59
observed in the	59
of an inactivated	59
is that the	59
t cells and	59
seasonal influenza vaccine	59
of health and	59
use in the	59
in cell culture	59
of maternal antibodies	59
sequence of the	59
copyright holder for	59
a lack of	59
are used to	59
in the study	59
large number of	59
dna vaccines are	59
holder for this	59
have been made	59
for the vaccine	59
of clinical trials	59
the advisory committee	58
reproductive and respiratory	58
a vaccine that	58
vaccination with a	58
has to be	58
high level of	58
and infectious diseases	58
protein of sars	58
in the present	58
results in the	58
immune responses by	58
memory b cells	58
mhc class ii	58
a protective immune	58
like particle vaccine	58
and respiratory syndrome	58
and use of	58
adaptive immune response	58
pandemic influenza vaccine	58
in the human	58
of ebola virus	58
been used in	58
against influenza virus	58
porcine reproductive and	58
dogs and cats	58
human clinical trials	57
due to a	57
which may be	57
united states and	57
the hepatitis b	57
after vaccination with	57
the virus and	57
to that of	57
that may be	57
in a mouse	57
of influenza viruses	57
vaccine in a	57
for the first	57
neutralizing antibodies in	57
and protective efficacy	57
found in the	57
the study of	57
for at least	57
the vaccine in	57
this is a	57
feline infectious peritonitis	57
vaccine safety and	56
similar to the	56
cellular immune response	56
similar to that	56
n a l	56
vaccines and the	56
comparison of the	56
vaccine can be	56
and mouth disease	56
a recent study	56
immunity in the	56
u r n	56
components of the	56
vaccines are available	56
be due to	56
j o u	56
influenza a and	56
led to a	56
changes in the	56
followed by a	56
the rate of	56
resulted in a	56
this article is	56
o u r	56
was observed in	56
the authors declare	56
can be achieved	56
responses induced by	56
humoral and cell	56
r n a	56
p r o	56
the most effective	56
human and animal	55
p r e	55
the virus to	55
of vaccines for	55
period of time	55
r o o	55
l p r	55
and adaptive immune	55
protection against influenza	55
immune response of	55
influenza vaccination in	55
a l p	55
at the end	55
appear to be	55
o o f	55
in balb c	55
infectious diseases and	55
are known to	55
all of the	55
immunity in mice	54
of vaccines to	54
in west africa	54
in accordance with	54
of vaccinia virus	54
and has been	54
neutralizing antibodies against	54
in young children	54
have the potential	54
delivery system for	54
caused by a	54
haemophilus influenzae type	54
of the pathogen	54
of influenza vaccines	54
in the respiratory	54
a mouse model	54
in phase i	54
immunization of mice	54
of the target	54
in insect cells	54
the burden of	54
immune responses are	54
they can be	54
approved by the	54
of infectious disease	54
are being developed	53
is able to	53
innate immune responses	53
an h n	53
can be found	53
vaccine development is	53
in infants and	53
the most promising	53
of a single	53
characterization of the	53
ebola virus disease	53
be associated with	53
response in mice	53
of a pandemic	53
is needed to	53
hepatitis c virus	53
it will be	53
dose of the	53
leading to the	53
to understand the	53
to respond to	53
children and adults	53
dna vaccine encoding	53
th and th	52
wide variety of	52
in older adults	52
to overcome the	52
the proportion of	52
the course of	52
vaccine candidates in	52
of a dna	52
in the lungs	52
to identify the	52
the influence of	52
avian influenza a	52
immune system to	52
safety of a	52
one or more	52
of dna vaccine	52
prior to the	52
of zika virus	52
control of the	52
is the first	52
at high risk	52
has been a	52
immune response that	52
in the world	52
the evaluation of	52
of the safety	52
is thought to	52
such as those	52
studies of the	51
mediated immune response	51
is essential for	51
respiratory syndrome virus	51
compared with the	51
effectiveness of the	51
polymerase chain reaction	51
been used as	51
has been suggested	51
been tested in	51
to produce a	51
immune system and	51
for prevention of	51
by the vaccine	51
a phase iii	51
depends on the	51
route of administration	51
antibodies against the	51
of the current	51
canine distemper virus	51
disease in the	51
its ability to	50
phase iii trials	50
b and t	50
to prevent the	50
were shown to	50
type i ifn	50
was used for	50
t and b	50
the combination of	50
been reported to	50
together with the	50
against challenge with	50
the public health	50
is also a	50
the university of	50
of influenza vaccination	50
b cell responses	50
guidance for industry	50
the release of	50
proved to be	50
in developed countries	50
the genome of	50
of the product	50
a wide variety	50
of antibody responses	50
and that the	50
of neutralizing antibody	49
response to a	49
with a single	49
are required to	49
clinical trials of	49
h n avian	49
contact with the	49
allergy and infectious	49
zika virus infection	49
advances in the	49
to control the	49
classical swine fever	49
vaccine design and	49
for the induction	49
responses to the	49
systematic review and	49
characterization of a	49
was carried out	49
not yet been	49
yellow fever virus	49
are responsible for	49
national institutes of	49
has the potential	49
role of the	49
at room temperature	49
of the new	49
of the study	49
i and ii	49
and have been	49
the detection of	49
into the host	49
of respiratory syncytial	49
vaccine against the	49
infection in the	49
it is the	49
the magnitude of	49
need for a	49
clinical trial of	49
national institute of	49
the vaccine virus	49
response to vaccination	49
the influenza vaccine	48
of the global	48
a reduction in	48
increased risk of	48
taken up by	48
in comparison to	48
a dose of	48
monophosphoryl lipid a	48
version posted october	48
shown to induce	48
safety of the	48
draining lymph nodes	48
immunogenicity and efficacy	48
the m protein	48
local and systemic	48
phase i trial	48
that has been	48
in another study	48
regions of the	48
expression of a	48
n influenza viruses	48
in hong kong	48
clinical trials for	48
been shown that	48
the stability of	48
japanese encephalitis virus	48
live attenuated vaccine	48
response in the	48
induction of a	48
the value of	48
a study of	48
a novel coronavirus	47
of dendritic cells	47
studies have been	47
vaccines should be	47
the basis for	47
many of these	47
stability of the	47
clinical trials and	47
the evolution of	47
the adaptive immune	47
for protection against	47
it is likely	47
all of these	47
venezuelan equine encephalitis	47
been found to	47
for infectious diseases	47
delivery of dna	47
to have a	47
dna vaccines have	47
the virus in	47
vaccines may be	47
a vaccine to	47
cells of the	47
to predict the	47
differences in the	47
influenza h n	47
a universal influenza	46
able to induce	46
virus as a	46
also known as	46
the viral genome	46
the live attenuated	46
the middle east	46
influenza vaccine and	46
in this review	46
in the region	46
immunogenicity and protective	46
of vaccine efficacy	46
may result in	46
approved for use	46
leads to the	46
for many years	46
of the two	46
of allergy and	46
has been the	46
on the use	46
design of a	46
play a role	46
attributed to the	46
vaccines are not	46
b cell epitopes	46
the last years	46
to the immune	46
highly pathogenic avian	46
vaccine to prevent	46
and b cells	45
of the advisory	45
could be a	45
in a single	45
an inactivated vaccine	45
and may be	45
seem to be	45
the capacity to	45
the occurrence of	45
exposure to the	45
effect of the	45
the case for	45
identification of a	45
the goal of	45
due to its	45
is characterized by	45
a vaccine vector	45
inactivated influenza vaccines	45
of vaccine safety	45
introduction of the	45
duration of immunity	45
public health and	45
of the covid	45
dose of vaccine	45
which have been	45
were immunized with	45
proven to be	45
and young children	45
of dengue virus	45
strong immune response	45
recombinant vaccinia virus	45
may be used	45
production of a	45
the past decade	45
induced by the	45
the virus was	45
and effectiveness of	44
member of the	44
to the host	44
porcine epidemic diarrhea	44
amino acid residues	44
and systemic immune	44
yellow fever vaccine	44
the incubation period	44
a clinical trial	44
vaccine for the	44
antibodies to the	44
similar to those	44
phase iii clinical	44
in this regard	44
have been described	44
none of the	44
pneumococcal conjugate vaccine	44
may be the	44
the dna vaccine	44
is expected to	44
institutes of health	44
resulting in a	44
properties of the	44
can be produced	44
specific immune response	44
has been made	44
known to be	44
ability of the	44
vaccine to be	44
against a lethal	44
used as an	44
of the innate	44
in transgenic plants	44
transmission of the	44
in the treatment	43
vaccine candidates against	43
an example of	43
of morbidity and	43
should be considered	43
foot and mouth	43
systemic immune responses	43
these vaccines are	43
capable of inducing	43
an increased risk	43
and cellular immunity	43
is required to	43
and the development	43
more than of	43
reduction in the	43
ability to induce	43
the mechanisms of	43
in case of	43
clinical trials are	43
the centers for	43
the first time	43
respiratory tract disease	43
diseases of the	43
with a recombinant	43
preclinical and clinical	43
be required to	43
within the host	43
after the first	43
the t cell	43
region of the	43
is due to	43
there was a	43
by the fda	43
department of health	43
is the only	43
of vaccine candidates	43
to vaccine development	43
a large number	43
to the virus	43
ha and na	43
simian immunodeficiency virus	43
health and human	43
and do not	43
based on their	43
has recently been	43
regulatory t cells	43
vaccine construct was	43
associated molecular patterns	42
resulted in the	42
pattern recognition receptors	42
infectious diseases of	42
to be an	42
the likelihood of	42
the nasal cavity	42
mucosal immune system	42
the upper respiratory	42
the developing world	42
focus on the	42
plasmid dna encoding	42
are involved in	42
but it is	42
neutralizing antibody titers	42
number of cases	42
of patients with	42
the implementation of	42
the choice of	42
of a live	42
between the two	42
a hong kong	42
have demonstrated that	42
vaccine development for	42
epidemic diarrhea virus	42
found that the	42
intranasal administration of	42
in relation to	42
the inclusion of	42
for more than	42
infectious bronchitis virus	42
factors associated with	42
pathogenic avian influenza	42
of the major	42
and vaccine development	42
play an important	42
vaccines against infectious	42
of influenza in	42
associated lymphoid tissue	42
use of vaccines	42
vaccine should be	42
of lc m	41
shown in table	41
this vaccine is	41
of measles virus	41
the vaccine to	41
in the nasal	41
detected in the	41
at least one	41
being tested in	41
of t cell	41
the benefits of	41
is difficult to	41
is mediated by	41
of immunity to	41
the history of	41
response to influenza	41
protection against lethal	41
in children and	41
for the delivery	41
tumor necrosis factor	41
seems to be	41
of the three	41
develop a vaccine	41
characteristics of the	41
are shown in	41
of seasonal influenza	41
the range of	41
cytotoxic t lymphocyte	41
after a single	41
are capable of	41
the age of	41
infants and young	41
of this approach	41
clinical development of	41
the gastrointestinal tract	41
even in the	41
of protection against	41
results in a	41
for vaccine delivery	41
is composed of	41
phase clinical trial	41
health care providers	41
n avian influenza	41
protects mice against	41
compared to other	41
be safe and	41
delivery systems for	41
the extent of	41
to protect the	41
n influenza vaccine	41
coronavirus spike protein	41
depend on the	41
quality of the	41
binding to the	41
the advantages of	40
of viral replication	40
is likely that	40
of an effective	40
in this paper	40
oral delivery of	40
vaccines has been	40
immune responses induced	40
remains to be	40
results of the	40
the cell surface	40
dendritic cells and	40
will not be	40
the human population	40
major cause of	40
was the first	40
the general population	40
our understanding of	40
impact on the	40
the cause of	40
of which are	40
serve as a	40
patients with covid	40
is required for	40
mucosal immune response	40
clinical signs of	40
in the population	40
impact of the	40
the selection of	40
well as in	40
to the use	40
result of the	40
will continue to	40
of infection and	40
because of their	40
in a vaccine	40
to the antigen	40
the most widely	40
in public health	40
in the u	40
review and meta	40
in rhesus monkeys	40
has been observed	40
the advantage of	40
results from the	40
development of effective	40
identification of the	40
suggested that the	40
required for the	40
neutralizing antibody response	40
at risk of	40
and human services	40
delivery of vaccines	40
oral polio vaccine	40
valley fever virus	40
with the development	40
phase iii trial	40
has been found	40
adjuvanted h n	40
been made to	40
levels of neutralizing	40
antibody response in	40
there is also	40
influenza virus in	39
mechanisms of action	39
this may be	39
as one of	39
in the next	39
should be given	39
the central nervous	39
type of vaccine	39
to develop vaccines	39
have been observed	39
have led to	39
be found in	39
a group of	39
the synthesis of	39
which was not	39
respiratory disease in	39
better understanding of	39
the sars coronavirus	39
to meet the	39
low levels of	39
host immune response	39
also be used	39
for vaccine production	39
owing to the	39
the most commonly	39
doses of the	39
or in combination	39
adolescents and adults	39
randomised controlled trial	39
infectious diseases in	39
the prediction of	39
have been found	39
an outbreak of	39
to support the	39
it would be	39
rational design of	39
factors such as	39
is necessary to	39
the structure of	39
and the use	39
induction of protective	39
part of a	39
focused on the	39
in the following	39
of the adjuvant	38
safe and immunogenic	38
with the use	38
the degree of	38
the relationship between	38
component of the	38
beginning of the	38
the search for	38
hepatitis b vaccination	38
inactivated whole virus	38
s and s	38
linked immunosorbent assay	38
is protected by	38
a mixture of	38
with the potential	38
is not a	38
been reported in	38
which in turn	38
this approach is	38
respiratory tract infections	38
delivery of a	38
viral vector vaccines	38
should also be	38
institute of allergy	38
dependent on the	38
the past years	38
for vaccine design	38
responses to a	38
they do not	38
in the blood	38
in pregnant women	38
in the developing	38
of mrna vaccines	38
in a number	38
a vaccine candidate	38
it is clear	38
modified vaccinia ankara	38
be applied to	38
in the number	38
the vaccine has	38
that there are	38
is possible to	38
in some countries	38
immunized with a	38
and should be	38
of this study	38
the establishment of	38
in this context	38
could not be	38
s protein of	38
a decrease in	38
response against the	38
have focused on	38
to be considered	37
no conflict of	37
infectious bursal disease	37
form of the	37
of a sars	37
parainfluenza virus type	37
tetravalent dengue vaccine	37
treatment of influenza	37
and cytotoxic t	37
be needed to	37
the influenza a	37
for delivery of	37
and protective immunity	37
than that of	37
each of these	37
insights into the	37
in the environment	37
been made in	37
the preparation of	37
t cell epitope	37
of the infection	37
that they are	37
preprint in perpetuity	37
been observed in	37
attenuated influenza vaccine	37
were observed in	37
throughout the world	37
to influenza virus	37
a is the	37
the state of	37
version of the	37
are currently being	37
more than years	37
the s and	37
been developed to	37
be included in	37
the severe acute	37
leading cause of	37
derived from a	37
this preprint this	37
cytotoxic t cell	37
high titers of	37
for this preprint	37
is essential to	37
preprint this version	37
with the highest	37
vaccine virus selection	37
lead to a	37
the early s	37
animal models and	37
be attributed to	37
it was shown	37
the creation of	37
resulting in the	37
the advent of	37
which is the	37
in mammalian cells	37
is capable of	36
result in a	36
vaccine efficacy and	36
and mortality in	36
to get vaccinated	36
passive transfer of	36
for up to	36
influenza virus hemagglutinin	36
be achieved by	36
in veterinary medicine	36
the viral envelope	36
to be highly	36
recombinant newcastle disease	36
over the last	36
in europe and	36
complete protection against	36
to generate a	36
the immunogenicity and	36
report of the	36
and there is	36
the timing of	36
of the organism	36
the aim of	36
public health emergency	36
they are not	36
modified live virus	36
adjuvants such as	36
in the prevention	36
oral administration of	36
as early as	36
immune response by	36
will be needed	36
in vero cells	36
along with the	36
article is protected	36
is clear that	36
and lack of	36
can be a	36
as the most	36
the disease and	36
response induced by	36
mutations in the	36
to study the	36
a comparison of	36
data on the	36
the uk and	36
with the same	36
a strong immune	36
the national institute	36
antibodies in the	36
and subunit vaccines	36
protected by copyright	36
younger than years	36
be given to	36
to participate in	36
ministry of health	36
the epidemiology of	36
in which a	36
is similar to	36
vaccine development against	36
it was found	36
the face of	36
of the h	36
is known to	36
rabies virus glycoprotein	36
licensed for use	36
vaccination has been	36
transmissible gastroenteritis virus	36
estimated to be	35
linked to the	35
which has been	35
of immune cells	35
was not certified	35
is safe and	35
serious adverse events	35
prevention and treatment	35
majority of the	35
specific t cell	35
children younger than	35
global public health	35
in preclinical studies	35
certified by peer	35
a major cause	35
size of the	35
available under a	35
by peer review	35
well as a	35
in the late	35
for induction of	35
immunity induced by	35
virus infection and	35
be the most	35
intranasal immunization with	35
seasonal influenza vaccines	35
been suggested that	35
to develop an	35
the size of	35
induced by a	35
of pandemic influenza	35
not certified by	35
in a variety	35
the late s	35
if the vaccine	35
protein of the	35
followed by the	35
replication in the	35
of cases of	35
is a highly	35
was used as	35
the characteristics of	35
knowledge of the	35
in children with	35
avian h n	35
induction of immune	35
for the future	35
vaccines is the	35
with severe acute	35
would like to	35
the causative agent	35
the mucosal immune	35
the final vaccine	35
and protection against	35
diseases caused by	35
a phase ii	35
responses elicited by	35
vaccine is a	35
with the vaccine	35
can result in	35
vaccines are currently	35
of human papillomavirus	35
there are two	35
be effective in	35
can be easily	35
an urgent need	35
avian influenza viruses	35
animals and humans	35
in the design	35
the control group	35
do not have	35
with h n	35
are more likely	35
broad range of	34
in the body	34
any of the	34
is made available	34
as vaccine adjuvants	34
and immunogenic in	34
half of the	34
the near future	34
in nonhuman primates	34
by the us	34
be necessary to	34
patients with severe	34
a candidate vaccine	34
acute respiratory distress	34
of vaccines is	34
out of the	34
risk of severe	34
in the vaccinated	34
with a high	34
is to be	34
the probability of	34
in conjunction with	34
of infection in	34
the length of	34
in more than	34
in tissue culture	34
intranasal delivery of	34
effects of the	34
a subunit vaccine	34
types of vaccines	34
of the antibody	34
of the potential	34
diseases in the	34
of the spike	34
provide protection against	34
protection against infection	34
induce protective immunity	34
and activation of	34
licensed in the	34
responses against the	34
the st century	34
trial of a	34
a universal vaccine	34
homologous and heterologous	34
carried out in	34
efforts to develop	34
infants and children	34
in the upper	34
progress has been	34
current status of	34
were used for	34
of human immunodeficiency	34
of t cells	34
under a is	34
and b cell	34
a recombinant adenovirus	34
used to produce	34
for epidemic preparedness	34
phase ii clinical	34
made available under	34
in the face	34
the result of	34
in the near	34
it is made	34
for treatment of	34
in the current	34
would not be	34
immunity to influenza	34
vaccines to prevent	34
plasmid dna vaccines	34
in north america	34
vaccine vector for	34
they have been	34
days after the	34
after the second	34
a randomized controlled	34
were collected from	34
cytotoxic t cells	34
of a universal	34
vaccines are administered	34
of the recombinant	34
authors declare no	34
all age groups	34
recombinant adenovirus type	34
development of novel	34
that do not	34
vaccine efficacy in	34
of safety and	34
most of these	34
information about the	33
of all the	33
tested in a	33
suggest that the	33
and duration of	33
vaccine is not	33
studies on the	33
countries in the	33
the th century	33
and more than	33
to express the	33
protection against challenge	33
antibodies in mice	33
use in humans	33
respiratory distress syndrome	33
in both the	33
have been associated	33
immune response was	33
by the use	33
increased risk for	33
the risks of	33
license it is	33
is the major	33
because of its	33
to create a	33
at a dose	33
data suggest that	33
of the national	33
syncytial virus infection	33
correlate of protection	33
for the use	33
the start of	33
dna vaccine for	33
as a means	33
infection with a	33
to provide a	33
vaccines and vaccination	33
the analysis of	33
phase i trials	33
to global health	33
available in the	33
the distribution of	33
should be noted	33
have been licensed	33
dna vaccine against	33
also been used	33
during the first	33
the disease in	33
the purpose of	33
doses of vaccine	33
of the respiratory	33
have not yet	33
from patients with	33
use of this	33
was licensed in	33
is possible that	33
as an alternative	33
virus vaccine in	33
is related to	33
is the case	33
international license it	33
one dose of	33
as opposed to	33
the recognition of	33
the mmr vaccine	33
the capacity of	33
high risk of	33
as soon as	33
influenza vaccines in	33
has been associated	33
the outbreak of	33
humans and animals	33
a second dose	33
basis for the	33
in the mouse	32
and t cells	32
based vaccines have	32
of innate immune	32
studies have demonstrated	32
the next pandemic	32
of the dna	32
will be a	32
for production of	32
is used to	32
spike protein of	32
effect on the	32
both cellular and	32
immunity against the	32
viruses such as	32
the most advanced	32
reported in the	32
continue to be	32
vp and vp	32
be considered as	32
the secretion of	32
leading to a	32
have been evaluated	32
vaccines do not	32
and hepatitis b	32
it does not	32
the vaccine industry	32
contributed to the	32
vaccine delivery system	32
as long as	32
cholera toxin b	32
the vaccine antigen	32
of type i	32
oral immunization with	32
by means of	32
randomized controlled trial	32
result in the	32
in spite of	32
confer protection against	32
shown in figure	32
randomized clinical trial	32
with and without	32
and clinical trials	32
phase clinical trials	32
of newcastle disease	32
and the potential	32
number of studies	32
magnitude of the	32
is an urgent	32
and severity of	32
it is estimated	32
dna vaccine in	32
summarized in table	32
much of the	32
large numbers of	32
in vivo and	32
nucleic acid vaccines	32
used to develop	32
of rabies virus	32
that the virus	32
act as a	32
in the americas	32
this can be	32
against influenza a	32
have the ability	32
against the virus	32
has been proposed	32
vaccines such as	32
to determine whether	32
host immune responses	32
of the efficacy	32
pathogenic h n	32
of this virus	32
of a covid	32
of the individual	32
may have a	32
memory t cells	32
the limitations of	32
a high level	32
subunit vaccine against	32
a potential vaccine	32
antigens and adjuvants	32
human papilloma virus	32
a better understanding	32
of these viruses	32
for the expression	32
and humoral immunity	32
the novel coronavirus	32
neutralizing antibodies to	32
for vaccines and	32
been reported that	32
were challenged with	32
prophylactic and therapeutic	32
tlr and tlr	32
shown in fig	32
dna vaccines is	32
in this article	32
this study was	32
dendritic cells in	32
data from the	32
cell responses and	31
of a candidate	31
revealed that the	31
influenza virus vaccines	31
human challenge studies	31
vaccine could be	31
that are not	31
the outcome of	31
antibody responses against	31
from a single	31
pandemic influenza a	31
the management of	31
vaccine candidate against	31
protective immunity to	31
on the development	31
rapid development of	31
to play a	31
supported by the	31
ii clinical trials	31
the f protein	31
protection against a	31
were reported in	31
by dendritic cells	31
in clinical development	31
of the vector	31
of yellow fever	31
the replication of	31
global burden of	31
an oral vaccine	31
and induction of	31
feline immunodeficiency virus	31
canine visceral leishmaniasis	31
it is now	31
and of the	31
are summarized in	31
because it is	31
and prevention of	31
human and veterinary	31
by the world	31
children and adolescents	31
with hepatitis b	31
in a population	31
the placebo group	31
of up to	31
mode of action	31
second dose of	31
and mucosal immune	31
as a vector	31
health care workers	31
of the total	31
are required for	31
applied to the	31
amino acid sequence	31
a broad range	31
added to the	31
vaccine was developed	31
section of the	31
been approved for	31
and cellular responses	31
the protective efficacy	31
of the mrna	31
have been successfully	31
vaccine candidate for	31
by the host	31
and distribution of	31
vaccination with the	31
vaccine will be	31
highly pathogenic h	31
provided by the	31
have been proposed	31
vaccine is available	31
specific t cells	31
in protection against	31
was developed by	31
immune responses that	31
advantage of the	31
dependent enhancement of	31
a period of	31
in guinea pigs	31
and production of	31
the elderly and	31
is considered to	31
such as influenza	31
influenza vaccine is	31
a member of	31
phase ii trials	30
results showed that	30
vaccine development has	30
bovine viral diarrhea	30
vaccination and the	30
the eradication of	30
million doses of	30
the antigen and	30
believed to be	30
the initiation of	30
for this reason	30
vaccine candidates are	30
case of the	30
more than million	30
expressed on the	30
in such a	30
the humoral immune	30
countries such as	30
is dependent on	30
of the live	30
this is an	30
a set of	30
causative agent of	30
for vaccines against	30
events associated with	30
vaccine candidates for	30
associated with an	30
to provide protection	30
infection in mice	30
is not recommended	30
it has also	30
for the control	30
as a model	30
the first vaccine	30
respiratory tract infection	30
for the next	30
to the surface	30
also been shown	30
strategies have been	30
vaccine r d	30
dna vaccine induces	30
to compare the	30
presence of maternal	30
as in the	30
at this time	30
do not require	30
potential to be	30
to make the	30
on the immune	30
shown that the	30
access to vaccines	30
of recombinant proteins	30
to induce protective	30
to hepatitis b	30
domain of the	30
induces protective immunity	30
of novel coronavirus	30
host immune system	30
embryonated chicken eggs	30
the route of	30
routes of administration	30
are expected to	30
type i interferon	30
to be associated	30
to elicit a	30
the vaccine development	30
with influenza a	30
of a protective	30
and adaptive immunity	30
in the community	30
in vaccine design	30
and expression of	30
disease in humans	30
tomato leaf curl	30
the inactivated vaccine	30
by vaccination with	30
to the site	30
coalition for epidemic	30
for a new	29
antibody responses and	29
in a recent	29
consistent with the	29
vaccine as a	29
syndrome coronavirus spike	29
the daily risk	29
approaches have been	29
in one study	29
have already been	29
infection of the	29
the efficiency of	29
a source of	29
systematic review of	29
immune system of	29
adverse events following	29
emerging infectious disease	29
mediated by the	29
the formulation of	29
a vaccine in	29
equine encephalitis virus	29
the vaccine may	29
of an influenza	29
were detected in	29
antibodies directed against	29
there may be	29
infection with the	29
of vaccines that	29
been developed for	29
well tolerated and	29
vaccine may be	29
protection in mice	29
antigens have been	29
ensure that the	29
such as a	29
the construction of	29
fraction of people	29
of age or	29
and the risk	29
to address the	29
be noted that	29
of this disease	29
for the detection	29
ii clinical trial	29
areas of the	29
efficacy of an	29
of a plant	29
against respiratory syncytial	29
for vaccine and	29
only a few	29
should be used	29
of such vaccines	29
children in the	29
of this review	29
blood mononuclear cells	29
respect to the	29
in the lung	29
toxin b subunit	29
based on recombinant	29
vaccines against influenza	29
found to have	29
than years of	29
the amino acid	29
the stimulation of	29
and effective vaccines	29
it is difficult	29
this is not	29
a part of	29
isolated from the	29
at the beginning	29
by a single	29
face mask use	29
of a phase	29
was found that	29
the exception of	29
the percentage of	29
in the event	29
been developed and	29
is an effective	29
developed by the	29
for use as	29
to obtain a	29
children under years	29
to weeks of	29
for public health	29
is a need	29
immunized with the	29
was detected in	29
as high as	29
risk factors for	29
with a vaccine	29
short period of	29
outer membrane protein	29
was performed using	29
efficacy of vaccines	29
high degree of	29
number of vaccine	29
for hepatitis b	29
is believed to	29
vaccinated with the	29
daily risk of	29
ranging from to	29
of the drug	29
influenza vaccines and	29
influenza vaccine effectiveness	29
by reverse genetics	29
that a vaccine	29
vaccines are used	29
as it is	29
like particles as	29
to influenza vaccination	29
against the vaccine	29
authors declare that	28
an attenuated live	28
the scope of	28
made in the	28
studies showed that	28
of human and	28
potential vaccine candidates	28
of disease in	28
case fatality rate	28
data not shown	28
to be able	28
dna vaccines encoding	28
closely related to	28
will have to	28
interfere with the	28
that need to	28
emergence of a	28
the ebola virus	28
based vaccines are	28
proportion of the	28
less likely to	28
adverse events associated	28
the uptake of	28
by the who	28
viral vectors for	28
so that the	28
and live attenuated	28
unlikely to be	28
the prevention and	28
information on the	28
may have been	28
of the nasal	28
an area of	28
in southeast asia	28
cytokines such as	28
infection in humans	28
in a large	28
nasal delivery of	28
should be administered	28
to be developed	28
hepatitis a and	28
it possible to	28
are available for	28
the fi rst	28
immune system in	28
virus has been	28
responses in humans	28
to make a	28
may be due	28
the source of	28
been evaluated in	28
most commonly used	28
the efficacy and	28
to be addressed	28
through the use	28
of amino acids	28
the viral vector	28
cell immune responses	28
antigen in the	28
the benefit of	28
the department of	28
pathogens such as	28
which results in	28
which leads to	28
in south africa	28
vaccine is the	28
in the serum	28
absence of a	28
under the control	28
of at least	28
the n protein	28
structure and function	28
in the second	28
virus vaccine candidate	28
influenza virus challenge	28
peripheral blood mononuclear	28
at weeks of	28
burden of disease	28
challenge in mice	28
inactivated vaccines are	28
clinical trials have	28
a need for	28
two types of	28
to develop and	28
to cd t	28
adjuvant effect of	28
to achieve the	28
after immunization with	28
of pregnant women	28
to those of	28
in elderly persons	28
the opportunity to	28
vaccine research and	28
used in a	28
virus dna vaccine	28
to ensure the	28
and dna vaccines	28
that they have	28
and stability of	28
of edible vaccines	28
of the main	28
of nucleic acid	28
with influenza virus	28
the global vaccine	28
of the m	28
in most cases	28
there were no	28
is estimated that	28
based subunit vaccine	28
in the viral	28
dna vaccines against	28
with the exception	28
is not known	28
in the gut	28
of more than	28
vaccination of the	28
of vaccine administration	28
days after vaccination	28
of candidate vaccines	28
could lead to	28
regardless of the	28
site of injection	28
the antigen is	28
recommendation is to	28
the future of	28
human monoclonal antibody	28
the protection of	28
of the genome	28
for pandemic influenza	28
the regulation of	28
receptor binding domain	28
three doses of	27
in the intestine	27
immune responses were	27
results suggest that	27
limited number of	27
the european union	27
b cell epitope	27
susceptible to infection	27
are not yet	27
of antibodies to	27
before and after	27
human influenza a	27
specific cd and	27
aspects of the	27
inserted into the	27
emergence of new	27
the rabies virus	27
the oral route	27
the small intestine	27
kim et al	27
of b cells	27
approach has been	27
the transmission of	27
a major role	27
and delivery systems	27
live virus vaccines	27
is currently being	27
in health care	27
of the hiv	27
residues in the	27
vaccines against the	27
virus and the	27
vaccines are the	27
also been reported	27
cell and t	27
delivery of the	27
respiratory tract of	27
of subunit vaccines	27
of coronavirus disease	27
in healthy volunteers	27
the strength of	27
vaccine in children	27
portion of the	27
by the immune	27
to note that	27
length of the	27
context of the	27
one of these	27
samples were collected	27
the s subunit	27
but not in	27
suggests that the	27
virus is a	27
to years of	27
was shown that	27
feline leukemia virus	27
use of live	27
has not yet	27
more susceptible to	27
the diagnosis of	27
by binding to	27
vaccinated with a	27
the rest of	27
against ebola virus	27
increasing number of	27
weeks after the	27
in a murine	27
for infectious disease	27
challenge with a	27
for respiratory syncytial	27
such as hiv	27
recognized by the	27
as described in	27
infection and disease	27
reduce the risk	27
african green monkeys	27
use of an	27
for this purpose	27
for h n	27
the host cells	27
structural proteins of	27
used to identify	27
level of protection	27
there are also	27
in dogs and	27
infectious bovine rhinotracheitis	27
of safe and	27
broadly neutralizing antibodies	27
as an effective	27
be caused by	27
has yet to	27
replication of the	27
recognition of the	27
to public health	27
although there is	27
swine fever virus	27
of s protein	27
protein and the	27
in the process	27
using the same	27
phase i study	27
of vaccine antigens	27
and those with	27
those of the	27
the challenge of	27
in the use	27
up to of	27
t cell and	27
a means of	27
number of doses	27
and the united	27
the rational design	27
production of the	27
clinical evaluation of	27
leads to a	27
has resulted in	27
predicted to be	27
of the ha	27
use of adjuvants	27
memory cd t	27
was based on	27
in phase ii	27
enhance the immune	27
reported that the	27
and respiratory syncytial	27
the target antigen	27
this has been	27
of a virus	27
seen in the	27
of avian influenza	27
so as to	27
new generation of	27
the existence of	26
vaccine in humans	26
of the vaccinated	26
response that is	26
vectors have been	26
virus challenge in	26
a matter of	26
for control of	26
of exposure to	26
was tested in	26
can be developed	26
for veterinary use	26
risks associated with	26
which could be	26
indicated that the	26
and yellow fever	26
in china and	26
recombinant hepatitis b	26
animal and human	26
phase i and	26
the growth of	26
clinical trial in	26
immune response with	26
of carp virus	26
an effort to	26
phase i studies	26
responses to vaccines	26
vaccine would be	26
directed against the	26
have been published	26
status of the	26
dependent rna polymerase	26
have been extensively	26
well as to	26
sars and mers	26
production of antibodies	26
may be more	26
risk of exposure	26
age or older	26
cell epitope prediction	26
rather than the	26
is to use	26
there are some	26
vaccine to the	26
induced immune responses	26
enhance the immunogenicity	26
the cold chain	26
the complexity of	26
in transgenic tobacco	26
protective effect of	26
who did not	26
alone or in	26
in latin america	26
to activate the	26
like to thank	26
by immunization with	26
and the elderly	26
such a vaccine	26
response of the	26
use as a	26
the understanding of	26
is supported by	26
year of life	26
vaccine in adults	26
vaccination is a	26
attenuated influenza vaccines	26
a modified live	26
of the coronavirus	26
in lymph nodes	26
vaccines that have	26
has become a	26
a tlr agonist	26
compared with other	26
the adjuvant effect	26
as a consequence	26
to dendritic cells	26
in the netherlands	26
is a common	26
on the market	26
edible vaccines are	26
of the us	26
in the laboratory	26
shown to have	26
proteins of the	26
indicating that the	26
vaccine clinical trial	26
american academy of	26
of the cell	26
h n vaccines	26
large amounts of	26
and identification of	26
number of vaccines	26
of highly pathogenic	26
over years of	26
surface antigen in	26
between vaccination and	26
a need to	26
to a vaccine	26
the assessment of	26
vaccines are also	26
to the presence	26
onset of symptoms	26
although it is	26
of cervical cancer	26
the performance of	26
immune system is	26
protein in the	26
neutralizing antibodies were	26
against infection with	26
presence of the	26
under years of	26
we found that	26
against lethal challenge	26
mice vaccinated with	26
the levels of	26
cell culture systems	26
have been studied	26